Datroway Achieves First OS Benefit in Immunotherapy-Ineligible Triple-Negative Breast Cancer
First cancer drug to show OS benefit vs chemotherapy for TNBC patients ineligible for immunotherapy in landmark phase 3 trial.




We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Google Tag Manager simplifies the management of marketing tags on your website without code changes.